Butabindide
Modify Date: 2024-01-11 15:10:31
Butabindide structure
|
Common Name | Butabindide | ||
|---|---|---|---|---|
| CAS Number | 185213-03-0 | Molecular Weight | 393.43400 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C19H27N3O6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of ButabindideButabindide (UCL-1397) oxalate is a potent, selective tripeptidvl peptidase II (TPP II) inhibitor with Ki values of 7 nM and 10 μM for TPP II and TPP I, respectively. Butabindide oxalate inhibits TPP II to protect CCK-8 against inactivation[1][2]. |
| Name | (2S)-1-[(2S)-2-aminobutanoyl]-N-butyl-2,3-dihydroindole-2-carboxamide,oxalic acid |
|---|---|
| Synonym | More Synonyms |
| Description | Butabindide (UCL-1397) oxalate is a potent, selective tripeptidvl peptidase II (TPP II) inhibitor with Ki values of 7 nM and 10 μM for TPP II and TPP I, respectively. Butabindide oxalate inhibits TPP II to protect CCK-8 against inactivation[1][2]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 7 nM (TPP II) and 10 μM (TPP I)[1] |
| In Vitro | Butabindide (UCL-1397; 0-24 nM; membranes of rat cerebral cortex) oxalate inhibits TPP II activity of cerebral membranes[2]. |
| In Vivo | Butabindide (UCL-1397; 10 mg/kg; i.v.; for 20 min) oxalate inhibits the breakdown of CCK-8 in the gastrointestinal tract and increases satiety in mice[2]. Animal Model: Mice (25-30 g)[2] Dosage: 10 mg/kg Administration: Intravenous injection; for 20 minutes Result: Reduces food intake and elicits other behavioral concomitants of satiation. |
| Molecular Formula | C19H27N3O6 |
|---|---|
| Molecular Weight | 393.43400 |
| Exact Mass | 393.19000 |
| PSA | 153.52000 |
| LogP | 2.35910 |
| Butabindide oxalate |
| Nociceptin |
| Butabindide |